Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate -

États-Unis - anglais - NLM (National Library of Medicine)

granules india ltd - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir sulfate - unii:4mt4vie29p) -

États-Unis - anglais - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: • atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [ see use in specific populations ( 8.4) ].  • use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [ see microbiology ( 12.4)] . atazanavir capsules are contraindicated: • in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens- johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [ see warnings and precautions (

Irlande - anglais - HPRA (Health Products Regulatory Authority)

teva b.v. - atazanavir sulfate - capsule, hard - 150 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (
4 pi mutations). there are very limited data available from children aged 6 to less than 18 years

Irlande - anglais - HPRA (Health Products Regulatory Authority)

teva b.v. - atazanavir sulfate - capsule, hard - 200 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (
4 pi mutations). there are very limited data available from children aged 6 to less than 18 years

Irlande - anglais - HPRA (Health Products Regulatory Authority)

teva b.v. - atazanavir sulfate - capsule, hard - 300 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (
4 pi mutations). there are very limited data available from children aged 6 to less than 18 years (

Malte - anglais - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 150 mg - antivirals for systemic use

Malte - anglais - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 200 mg - antivirals for systemic use

Malte - anglais - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 300 mg - antivirals for systemic use